Ekso Bionics Holdings, Inc. (EKSO)

Ekso Bionics completed a 1-for-15 reverse stock split in May 2025. The company reported disappointing Q2 2025 earnings but showed strong recovery in Q3 2025. Ekso Bionics announced a $3.7 million registered direct offering of common stock. The company announced executive equity award grants. Ekso Bionics was upgraded to a Zacks Rank #2 (Buy). Ekso Bionics entered into an exclusive U.S. distribution agreement with MediTouch Inc. for its BalanceTutor™ rehabilitation system. Applied Digital and Ekso Bionics entered into a non-binding term sheet for a proposed business combination. Insider sentiment for EKSO has been negative. Over the 12 months through January 5, 2026, EKSO shares rose by 3.23%. As of February 6, 2026, the stock gained 11.22% on the last trading day.

Ekso Bionics has experienced fluctuations in demand, with "lumpy quarterly revenue" and weakness in demand for Enterprise Health devices in Q2 2025, followed by a rebound in Q3 2025. The company is working to bolster demand for its EksoNR device and expects an increasing contribution from its Personal Health products, particularly with the CMS approval for reimbursement of the Ekso Indego Personal device.

Ekso Bionics Holdings, Inc. specializes in wearable bionic exoskeletons for healthcare and industrial applications, aiming to enhance human mobility, strength, and endurance. The company operates in the medical sector, focusing on therapeutic devices and advanced medical equipment. Its products include EksoNR, EksoGT, Ekso Indego Therapy, Ekso Indego Personal, EksoVest, EksoZeroG, Ekso EVO, and BalanceTutor™.

Ekso Bionics serves a global customer base in the United States, Europe, and Asia. All of the company's operations are held in the United States, with its corporate office in San Rafael, California. The regions the company operates in include the Americas, EMEA (Europe, Middle East, and Africa), and APAC (Asia-Pacific).

Ekso Bionics has a history of positive recognition, including being selected as Wired magazine's number two "Most Significant Gadget of 2010" and included in Time magazine's "50 Best Innovations of 2010." The company outlined a strategic initiative to build a proprietary foundation model for human motion and integrate new artificial intelligence (AI) capabilities across its devices. The company launched eksoUniversity, a new platform offering continuing education courses for physical therapists and assistants. An exoskeleton study by Ekso Bionics was highlighted as a "Potential Game-Changer for Health and Finance." The exclusive distribution agreement with MediTouch Inc. for the BalanceTutor™ rehabilitation system in the U.S. further solidifies its market presence. The proposed business combination to form ChronoScale Corporation represents a significant strategic shift that could broaden the company's reputation beyond medical devices into the rapidly growing AI infrastructure market.

Ekso Bionics Holdings, Inc. has 34 institutional owners and shareholders holding a total of 161,551 shares, with approximately 6.42% of the stock owned by institutional investors. Major institutional owners include Citadel Advisors Llc and Vanguard Group Inc. Key individual owners include Daniel Asher, Scott Davis (CEO), and Corinna Lathan (Director).